drugset / Trial / NCT06594965
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HS-20106 on anemia in patients with very low, low or intermediate risk MDS.
Timeline
- Start
- 2024-10-30
- Primary completion
- 2025-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-20106 | Unknown | — | Subcutaneous |